Astrazeneca Plc Stock Total Debt
| AZNCF Stock | USD 125.50 0.80 0.64% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Pink Sheet. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC pink sheet.
AstraZeneca |
AstraZeneca PLC Company Total Debt Analysis
AstraZeneca PLC's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current AstraZeneca PLC Total Debt | 22.96 B |
Most of AstraZeneca PLC's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, AstraZeneca PLC has a Total Debt of 22.96 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The total debt for all United States stocks is significantly lower than that of the firm.
AstraZeneca Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in total debt category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X | |||
| Price To Sales | 4.73 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.33 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 2.11 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Number Of Employees | 42 | |||
| Beta | 0.19 | |||
| Market Capitalization | 215.86 B | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 6.38 B | |||
| Working Capital | (2.52 B) | |||
| Current Asset | 12.87 B | |||
| Current Liabilities | 15.38 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.01 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.